News Archive

April 2018

• Media ReleaseApr 19, 2018

  AveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of Neurology

  Includes Initial Data from SMA Type 1 Pivotal Trial (STR1VE) and 24-Month Follow-Up Data from Phase 1 Trial CHICAGO, April 19, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a…
• Key ReleaseApr 19, 2018

  Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer

  Basel, April 19, 2018 - Novartis announced today the appointment of John Tsai, M.D. as Head of Global Drug Development (GDD) and Chief Medical Officer. Dr. Tsai will join Novartis on May 1, 2018, and…
• Media ReleaseApr 19, 2018

  Novartis verzeichnet ein starkes erstes Quartal und ergreift Schritte, um ein stärker fokussiertes Arzneimittelunternehmen zu werden

  Der Nettoumsatz steigt um 4% (kWk[1], +10% USD), vor allem dank folgender Beiträge: Entresto wächst um 126% (kWk) auf USD 200 Millionen, da es weltweit vermehrt eingesetzt wird Cosentyx legt um…
• Media ReleaseApr 19, 2018

  Novartis delivered a strong first quarter and acted to become a more focused medicines company

  Net sales grew 4% (cc[1], +10% USD) mainly driven by: Entresto grew to USD 200 million, +126% (cc) driven by increased uptake world wide Cosentyx was USD 580 million, +35% (cc) with strong…
• Media ReleaseApr 19, 2018

  Novartis a réalisé une bonne performance au premier trimestre et agi pour devenir une entreprise plus centrée sur les médicaments

  Hausse du chiffre d'affaires net de 4% (tcc[1], +10% USD), stimulée principalement par: Entresto, qui a atteint USD 200 millions, soit +126% (tcc), soutenu par son adoption croissante dans le…
• Media ReleaseApr 18, 2018

  Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders

  Deal includes reSET®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O(TM), potential treatment pending FDA clearance for patients with Opioid Use Disorder treated…
• Media ReleaseApr 17, 2018

  Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures

  The LIBERTY trial studied patients with episodic migraine who had failed 2 to 4 prior treatments, a uniquely difficult-to-treat population often excluded from migraine prevention trials  …
• Media ReleaseApr 17, 2018

  Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials

  Company to invest more than USD 100 million to advance research and development of new antimalarials over the next five years Commitment includes expanding access to pediatric antimalarials and…
• Media ReleaseApr 17, 2018

  Novartis bekräftigt Engagement zur Eliminierung von Malaria und investiert USD 100 Millionen in die Erforschung und Entwicklung der nächsten Generation von Malariamedikamenten

  Das Unternehmen investiert in den kommenden fünf Jahren über USD 100 Millionen, um die Erforschung und Entwicklung neuer Malariamedikamente voranzutreiben Das Engagement beinhaltet einen Ausbau…
• Media ReleaseApr 17, 2018

  Novartis renouvelle son engagement afin d'éliminer le paludisme en investissant 100 millions de dollars dans la recherche et le développement d'antipaludiques de nouvelle génération

  L'entreprise s'apprête à investir plus de 100 millions de dollars afin de faire progresser la recherche et le développement de nouveaux antipaludiques au cours des cinq prochaines années L'…
• Key ReleaseApr 17, 2018

  Novartis tender offer for AveXis commences

  Basel, April 17, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that its indirect wholly-owned subsidiary, Novartis AM Merger Corporation, a Delaware corporation ("Purchaser"), has…
• Media ReleaseApr 16, 2018

  Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes

  Heart failure (HF) patients with reduced ejection fraction treated with Entresto experienced significantly less reduction in kidney function compared to patients treated with standard of care ACE…